Literature DB >> 19660184

Common genetic coagulation variants are not associated with ischemic stroke in a case-control study.

Susanna Moskau1, Kerstin Smolka, Alexander Semmler, Dirk Schweichel, Ursula Harbrecht, Jens Müller, Christoph Pohl, Thomas Klockgether, Michael Linnebank.   

Abstract

OBJECTIVE: Abnormalities in the coagulation pathway are often included in the diagnostic work-up of stroke patients, especially in young adults with cryptogenic stroke.
METHODS: Three common genetic variants within the coagulation cascade were investigated in 500 control subjects and in 167 patients with ischemic stroke defined by TOAST subclassification. Analysed variants were factor V Leiden, prothrombin 20210G-->A and factor XIII Val34Leu.
RESULTS: The factor V Leiden mutation was over-represented in patients with cardioembolic stroke for trend, whereas the prothrombin 20210G-->A variant and the factor XIII polymorphism Val34Leu were not associated with stroke of any subtype. The three polymorphisms showed no association with stroke in subgroups of patients defined by age (<40, 40-49, 50-59, > or =60 years). DISCUSSION: This study suggests that the analysis of prothrombin 20210G-->A and factor XIII Val34Leu is not a useful diagnostic procedure in the work-up of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660184     DOI: 10.1179/016164109X12464612122533

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  2 in total

1.  Coagulation Factor XIII Val34Leu Polymorphism in the Prediction of Premature Cardiovascular Events-The Results of Two Meta-Analyses.

Authors:  Beata Sarecka-Hujar; Danuta Łoboda; Elżbieta Paradowska-Nowakowska; Krzysztof S Gołba
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

2.  Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.

Authors:  Markus Alexander Thaler; Regina Feurer; Christoph Thaler; Natalie Sonntag; Michael Schleef; Ina-Christine Rondak; Holger Poppert
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.